Castellino, S. M., Giulino‐Roth, L., Harker‐Murray, P., Kahn, J. M., Forlenza, C., Cho, S., Hoppe, B., Parsons, S. K., & Kelly, K. M. (2023). Children’s Oncology Group’s 2023 blueprint for research: Hodgkin lymphoma. Pediatric Blood & Cancer, 70(S6). Portico. https://doi.org/10.1002/pbc.30580

Suzuki, Y., Zhou, S., Ota, Y., Harrington, M., Miyagi, E., Takagi, H., Kuno, T., & Wright, J. D. (2023). Toxicity profiles of antibody-drug conjugates for anticancer treatment: a systematic review and meta-analysis. JNCI Cancer Spectrum, 7(5). https://doi.org/10.1093/jncics/pkad069

Mair, M. J., Bartsch, R., Le Rhun, E., Berghoff, A. S., Brastianos, P. K., Cortes, J., Gan, H. K., Lin, N. U., Lassman, A. B., Wen, P. Y., Weller, M., van den Bent, M., & Preusser, M. (2023). Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours. Nature Reviews Clinical Oncology, 20(6), 372–389. https://doi.org/10.1038/s41571-023-00756-z

Loibl, S., Loirat, D., Tolaney, S. M., Punie, K., Oliveira, M., Rugo, H. S., Bardia, A., Hurvitz, S. A., Brufsky, A. M., Kalinsky, K., Cortés, J., O’Shaughnessy, J. A., Dieras, V., Carey, L. A., Gianni, L., Gharaibeh, M., Preger, L., Phan, S., Chang, L., … Piccart, M. J. (2023). Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. European Journal of Cancer, 178, 23–33. https://doi.org/10.1016/j.ejca.2022.10.003

Chen, L. N., & Carvajal, R. D. (2022). Tebentafusp for the treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma. Expert Review of Anticancer Therapy, 22(10), 1017–1027. https://doi.org/10.1080/14737140.2022.2124971

O’Shaughnessy, J., Brufsky, A., Rugo, H. S., Tolaney, S. M., Punie, K., Sardesai, S., Hamilton, E., Loirat, D., Traina, T., Leon-Ferre, R., Hurvitz, S. A., Kalinsky, K., Bardia, A., Henry, S., Mayer, I., Zhu, Y., Phan, S., & Cortés, J. (2022). Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Research and Treatment, 195(2), 127–139. https://doi.org/10.1007/s10549-022-06602-7

Carvajal, R. D., Nathan, P., Sacco, J. J., Orloff, M., Hernandez-Aya, L. F., Yang, J., Luke, J. J., Butler, M. O., Stanhope, S., Collins, L., McAlpine, C., Holland, C., Abdullah, S. E., & Sato, T. (2022). Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. Journal of Clinical Oncology, 40(17), 1939–1948. https://doi.org/10.1200/jco.21.01805

Rosenblat, T. L., McDevitt, M. R., Carrasquillo, J. A., Pandit-Taskar, N., Frattini, M. G., Maslak, P. G., Park, J. H., Douer, D., Cicic, D., Larson, S. M., Scheinberg, D. A., & Jurcic, J. G. (2022). Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab. Clinical Cancer Research, 28(10), 2030–2037. https://doi.org/10.1158/1078-0432.ccr-21-3712

Liu, A. W., Wei, A. Z., Maniar, A. B., & Carvajal, R. D. (2022). Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors. Expert Opinion on Biological Therapy, 22(8), 997–1004. https://doi.org/10.1080/14712598.2022.2031970